History

2010		Cosmo Pharmaceuticals announces preliminary interim result of its tender offer for BioXell
2009		Cosmo's CB-03-01 phase II pilot study in acne demonstrates superiority over Retin A® on 11 December Cosmo publishes the public tender offer to acquire BioXell on 8 December Cosmo offers to acquire BioXell on 18 November
2008		Strategic collaboration with Santarus for U.S rights to Budesonide MMX® and Rifamycin MMX® on 15 December Licensing agreement with Dr. Falk for Rifamycin SV MMX® Cosmo awarded US patent for use of its MMX® technology
2007		UK Market launch of Mezavant XL® by Shire plc on 05 November. Licensing agreement with Ferring for Budesonide MMX™ US Market launch of Lialda® by Shire plc on 19 March. IPO on the Swiss Stock Exchange (SWX) on 12 March.
2006		FDA approval for the manufacturing of tablets to the USA. Completion of 2.000 sq m plant in Lainate, Milan.
2005		Completion of first financing round of €20.4 million by Cosmo Holding S.p.A. Lialda®/Mezavant® Supply Agreement with Shire plc.
2004		Opening of an R&D laboratory in Catania, Italy.
2001		Lialda®/Mezavant® globally out-licensed to Giuliani S.p.A./ Shire plc*.
1999		Filing of the first MMX® Multi Matrix technology patent for the controlled release of tablets in the gastro-intestinal tract.
1998		Strategic decision to develop novel oral formulations of off-patent pharmaceutical products to generate new patentable applications.
1997		Foundation of Cosmo S.p.A. by purchasing contract manufacturing unit in Lainate (Milan) from Parke Davis (now Pfizer Group).

*sublicensed